Abstract
Novo Nordisk will pay Dicerna Pharmaceuticals $225 million, which includes up-front fees and an equity investment, as part of a broad collaboration to develop RNAi-based therapies targeting liver-related diseases. Dicerna’s technology platform hinges on using a substrate for an enzyme called Dicer to deliver a drug into cells, where it can turn off a specific gene. The companies will work on more than 30 liver cell targets, including ones implicated in nonalcoholic steatohepatitis, type 2 diabetes, and obesity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
